Candel's biomarker study backs up its Phase 3 prostate cancer data, not the trial itself
A mechanistic Phase 2 study of CAN-2409 is set to report immune biomarker data in Q3 2026, supporting evidence for a BLA Candel plans to file on separate Phase 3 results.
Executive Summary
- Candel Therapeutics is running a mechanistic biomarker study of CAN-2409 in localized prostate cancer, designed with FDA input, that is meant to support the mechanistic case behind separate Phase 3 survival data rather than generate a new efficacy result on its own.
- The trial's primary measure is biodistribution and immune activity, not a clinical endpoint, so the Q3 2026 data will read as mechanistic support rather than a decision-grade efficacy signal.
- The trial's enrollment target and completion timeline both moved in the same February update, changes that reflect routine registry housekeeping for a still-recruiting, non-registrational Phase 2 study rather than a trial in distress.
- No other industry-sponsored trial targets HSV-TK in localized prostate cancer, leaving this mechanistic study without a direct peer to benchmark against inside the indication.
- The real catalyst for CAN-2409 in prostate cancer is the planned regulatory filing built on the Phase 3 disease-free-survival data; this study's job is to reinforce the biological story behind that filing, not to replace it.
The catalyst
Candel Therapeutics said in its third-quarter 2025 corporate update that it designed a supportive, mechanistic clinical trial of CAN-2409 in localized prostate cancer in collaboration with the FDA, and that it plans to release immunologic biomarker data from that study in the third quarter of 2026. The trial, registered as NCT07332000, tests biodistribution of aglatimagene besadenovec as its primary measure, with treatment-emergent adverse event incidence as a secondary endpoint. It is a Phase 2, non-registrational study enrolling adult men with favorable intermediate-risk localized prostate cancer and an ECOG performance status of 0 to 2. Candel+1Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsNov 13, 2025A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecNCT07332000
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the endpoint measures
Biodistribution measures where the viral construct localizes and how the immune system responds after intra-prostatic injection, not tumor response or survival. That places the trial's information value in a different register than a clinical efficacy readout: results due in the stated window running from July 1 to September 30, 2026 will show whether the biological activity underlying CAN-2409's mechanism is detectable and consistent with the disease-free-survival signal Candel has already reported from its separate Phase 3 trial, not whether the drug works in a new cohort. NCT07332000+1A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecNCT07332000Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsNov 13, 2025
The Phase 3 backdrop
Candel's CEO, Paul Peter Tak, said the company presented subgroup analyses from the Phase 3 prostate cancer trial at the American Society for Radiation Oncology's 2025 meeting showing improved prostate cancer-specific disease-free survival independent of the type of external beam radiation therapy used, and that it plans to submit a BLA for CAN-2409 in intermediate-to-high-risk localized prostate cancer in the fourth quarter of 2026. The mechanistic study reporting in Q3 2026 sits ahead of that filing on the calendar, positioned to reinforce the biological rationale the BLA will lean on rather than to generate a new pivotal result. CandelCandel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsNov 13, 2025
Trial conduct
The trial's enrollment target rose from 30 to 45 patients and its primary completion date moved from June 1 to August 1, 2026, both changes recorded in the same registry update on February 19, 2026. An enrollment increase in a Phase 2 study alongside a two-month completion shift is within the range of routine protocol housekeeping for a trial that remains in active recruitment, and the study has not shown signs of stalled enrollment or dormancy. NCT07332000A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecNCT07332000
Competitive frame
No other industry-sponsored trial targets HSV-TK in localized prostate cancer, and the broader Viral Gene Expression mechanism class shows limited recent activity in the indication, with the field's HSV-TK-specific trial count showing zero new studies against six older ones. Candel's own pipeline includes a Phase 3 trial of the same drug in non-small cell lung cancer, sharing the HSV-TK target and gene-therapy modality, but that program targets a different indication and disease biology. Within prostate cancer, comparators from radiopharmaceuticals, androgen-receptor inhibitors, and PARP inhibitors run in Phase 3, but none share CAN-2409's target or mechanism class, leaving this mechanistic study without a direct peer to benchmark against.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.